Waters Corporation ACQUITY Premier System: UHPLC workhorse for demanding labs

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 7:34:51 PM ET. Details in the imprint.

The ACQUITY Premier System from Waters Corporation is a premium ultra-high-performance liquid chromatography (UHPLC) platform aimed at laboratories that cannot compromise on sensitivity, robustness, and sample integrity. Waters positions the system as a solution to reduce metal-analyte interactions through its MaxPeak High Performance Surfaces technology, helping lab teams recover more of their analytes with better peak shapes and more consistent quantitation across runs. The system is part of Waters' ACQUITY family of LC instruments and is available for customers in the United States with configurations tailored for small-molecule, biopharmaceutical, and food and environmental testing workflows directly from Waters and authorized distributors.

What the ACQUITY Premier System is designed to do

At its core, the ACQUITY Premier System is a UHPLC platform that combines high operating pressure with low dispersion to enable fast separations and high-resolution chromatographic results. According to Waters, the system is built on the ACQUITY UPLC architecture but adds MaxPeak surface technology to mitigate issues caused by metal-sensitive compounds, such as phosphopeptides, oligonucleotides, and certain organic acids. By applying an engineered surface throughout the fluidic path, Waters states that the ACQUITY Premier System can reduce analyte adsorption, leading to improved recovery and reproducibility for challenging analytes.

Typical configurations pair the ACQUITY Premier System with Waters' column offerings and detectors to form complete LC solutions. Customers can combine the system with UV/UV-Vis detection, photodiode array detection, or mass spectrometry, including Waters mass spectrometers such as Xevo or Synapt series, depending on the application and required sensitivity. In biopharmaceutical labs, the system is often used for peptide mapping, glycan analysis, and charge variant profiling, while in small-molecule labs it supports impurity profiling, stability testing, and QA/QC release testing. For many regulated laboratories, the ability to integrate the system into compliant data management workflows is central, and Waters positions the platform as compatible with its own Empower chromatography data system software.

Waters highlights that the ACQUITY Premier System offers operating pressures up to the typical UHPLC range with fast gradient capabilities, allowing laboratories to shorten run times while maintaining separation quality. By combining short columns packed with sub-2-micron particles and precisely controlled gradients, labs can often achieve the same or better resolution in significantly less time compared with conventional HPLC, which is relevant for high-throughput quality control and method development. Reduced run times also mean lower solvent consumption, which can translate into lower operating costs and less waste per sample.

From a hardware design perspective, the system is built around modular components, including a sample manager (autosampler), binary or quaternary solvent manager, and column manager for precise temperature control. This modular approach allows labs to configure the system to their current needs and upgrade later as workflows evolve. Features such as low-carryover injection paths, precise temperature management, and optimized fluidics aim to maintain chromatographic stability during long sequences.

Key features and differentiation

One of the features that sets the ACQUITY Premier System apart is Waters' MaxPeak High Performance Surfaces technology. Traditional stainless-steel fluidic paths can interact with analytes carrying certain functional groups, causing adsorption, peak tailing, or loss of response, particularly for low-level or metal-sensitive species. MaxPeak surfaces are engineered coatings applied to wetted metal components to act as a barrier between analytes and the underlying metal, which Waters says can enhance analyte recovery, improve peak shapes, and increase sensitivity for difficult analytes. For labs working with biotherapeutics or phosphorylated compounds, this can help reduce method development time and improve robustness when transferring methods between instruments.

In addition, the ACQUITY Premier System is designed to support a wide range of operating pH conditions to align with many reversed-phase, hydrophilic interaction (HILIC), ion-pair, and ion-exchange separations. This versatility allows labs to cover multiple application types with one platform, rather than maintaining separate dedicated systems for each chemistry. Combined with Waters' column portfolio, the platform is marketed as a flexible backbone for chromatography methods in pharmaceutical, life science, and food testing environments.

Waters also emphasizes the system's integration with its Empower chromatography data system, which is widely deployed in regulated pharmaceutical and biopharmaceutical labs. Empower integration supports electronic records, audit trails, and secure access control required under regulations such as FDA 21 CFR Part 11 and EU Annex 11, making the ACQUITY Premier System suitable for GxP environments. For IT and quality units, having a UHPLC platform that ties directly into existing validated CDS infrastructure can reduce the overhead associated with bringing new instruments online.

For users, the practical advantages of the ACQUITY Premier System include fast start-up and equilibration times, support for various injection volumes, and options for sample cooling to protect temperature-sensitive compounds. The system is built to handle long unattended runs, an important feature for labs operating overnight or during weekends. Enhanced diagnostic tools and serviceability aim to limit downtime, with Waters offering global service and support contracts to keep systems within performance specifications.

From a market perspective, the ACQUITY Premier System extends Waters' long-running ACQUITY UPLC platform, which helped popularize UHPLC in pharma and analytical labs. UHPLC has become standard for many chromatographic assays, and by adding surface engineering tailored for metal-sensitive analytes, Waters is attempting to defend and grow its installed base as workflows become more complex. Competitors also offer UHPLC platforms, but Waters is positioning MaxPeak technology and its biopharma- and oligo-focused performance as a differentiator for labs that deal frequently with these analyte classes.

For buyers evaluating instruments in this category, key questions often include instrument uptime, method transferability, regulatory support, and vendor service. The ACQUITY Premier System targets these points with backward-compatible method transfer from existing ACQUITY platforms, Empower CDS integration, and a service infrastructure that leverages Waters' installed base in pharmaceutical and life science companies. This positioning is relevant for both central R&D facilities and QC labs that need a robust platform with predictable maintenance requirements and long-term support.

For Waters Corporation, high-performance LC systems such as the ACQUITY Premier System form an important part of its analytical instrument portfolio, supporting recurring revenue from columns, consumables, and service. Shares of Waters Corp (US9418481035, ticker WAT) traded at levels reported on the New York Stock Exchange in mid-2026 according to recent market data.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.